Equities research analysts expect Hologic, Inc. (NASDAQ:HOLX) to report earnings of $0.49 per share for the current quarter, according to Zacks. Seven analysts have made estimates for Hologic’s earnings, with the lowest EPS estimate coming in at $0.48 and the highest estimate coming in at $0.49. Hologic posted earnings per share of $0.52 during the same quarter last year, which indicates a negative year-over-year growth rate of 5.8%. The business is expected to issue its next quarterly earnings results on Wednesday, November 1st.

On average, analysts expect that Hologic will report full-year earnings of $2.01 per share for the current year, with EPS estimates ranging from $2.00 to $2.01. For the next financial year, analysts expect that the company will report earnings of $2.17 per share, with EPS estimates ranging from $2.06 to $2.28. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for Hologic.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.49 by $0.01. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The company had revenue of $806.10 million for the quarter, compared to the consensus estimate of $799.70 million. During the same quarter in the previous year, the company earned $0.51 EPS. Hologic’s quarterly revenue was up 12.4% compared to the same quarter last year.

Several equities research analysts have weighed in on HOLX shares. Royal Bank Of Canada cut their price target on Hologic from $50.00 to $45.00 and set a “sector perform” rating on the stock in a report on Thursday, August 3rd. BidaskClub cut Hologic from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Zacks Investment Research raised Hologic from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Barclays PLC decreased their target price on Hologic from $53.00 to $51.00 and set an “overweight” rating for the company in a research report on Thursday, August 3rd. Finally, Needham & Company LLC reissued a “buy” rating on shares of Hologic in a research report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nine have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $48.64.

TRADEMARK VIOLATION NOTICE: “Brokerages Expect Hologic, Inc. (HOLX) Will Announce Earnings of $0.49 Per Share” was published by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/09/20/brokerages-expect-hologic-inc-holx-will-announce-earnings-of-0-49-per-share.html.

In other Hologic news, VP Karleen Marie Oberton sold 4,704 shares of the stock in a transaction on Monday, July 17th. The stock was sold at an average price of $45.19, for a total transaction of $212,573.76. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Elaine Ullian sold 6,902 shares of the stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $40.12, for a total value of $276,908.24. Following the sale, the director now owns 23,810 shares in the company, valued at approximately $955,257.20. The disclosure for this sale can be found here. Insiders sold a total of 27,594 shares of company stock valued at $1,168,871 over the last ninety days. 0.79% of the stock is currently owned by company insiders.

Large investors have recently made changes to their positions in the business. Hall Laurie J Trustee grew its holdings in Hologic by 10.2% during the 2nd quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock valued at $110,000 after buying an additional 225 shares during the last quarter. Commonwealth Bank of Australia grew its holdings in Hologic by 31.0% during the 2nd quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock valued at $114,000 after buying an additional 600 shares during the last quarter. MPS Loria Financial Planners LLC acquired a new stake in Hologic during the 2nd quarter valued at $191,000. National Asset Management Inc. acquired a new stake in Hologic during the 2nd quarter valued at $203,000. Finally, Miles Capital Inc. acquired a new stake in Hologic during the 1st quarter valued at $206,000. Hedge funds and other institutional investors own 96.38% of the company’s stock.

Hologic (HOLX) traded up 0.687% on Friday, hitting $37.385. 2,177,353 shares of the company were exchanged. Hologic has a 52 week low of $35.15 and a 52 week high of $46.80. The company has a market capitalization of $10.49 billion, a price-to-earnings ratio of 13.924 and a beta of 0.92. The stock has a 50 day moving average of $38.51 and a 200 day moving average of $42.55.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Get a free copy of the Zacks research report on Hologic (HOLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.